A Medical Promise That Did Not Match the Science
For years, Americans have been told a comforting story about marijuana. It is natural. It is safer than other drugs. It treats pain, anxiety, insomnia, and a long list of modern problems. Dispensaries present cannabis as if it were a wellness product, and the phrase “medical marijuana” makes it sound like a proven therapy.
A major new analysis says that story does not hold up.
A comprehensive review published in JAMA examined more than 2,500 scientific papers from the last 15 years, including clinical trials, guidelines, and other reviews focused on medical cannabis. The researchers concluded that for most conditions people claim cannabis treats, the evidence is weak, inconsistent, or simply not there.
Dr. Michael Hsu of UCLA, the lead author, said the gap between what people believe and what science shows is large. “Our review highlights significant gaps between public perception and scientific evidence,” he said.
This is not a small or technical argument. It cuts to the heart of how the public has been marketed a drug as medicine, while real proof is limited and real risks are increasing.
The analysis was led by UCLA, with contributions from Harvard, UC San Francisco, Washington University School of Medicine, and New York University. The team set out to evaluate how strong the medical evidence really is and to offer clinical guidance based on what research can support.
The review looked across many types of studies, including randomized trials. Those are the gold standard because they can test whether a treatment actually helps, rather than simply being associated with change.
The authors also noted limits. This was a narrative review, not a systematic review, meaning it did not use strict standardized methods designed to reduce bias in how studies are selected. They also noted that some evidence comes from observational research, which cannot establish cause and effect. Even with those caveats, the direction of the findings was clear: strong evidence exists for only a narrow set of uses, while the broader medical narrative is mostly unsupported.
The Big Finding: Most Medical Claims Are Not Proven
The review found that evidence supporting most medical uses of cannabis or cannabinoids is limited or insufficient.
That matters because the most common reasons people cite for “medical” cannabis are conditions like chronic pain, insomnia, anxiety, and post traumatic stress disorder. Yet the review reported that randomized trials did not support meaningful benefit for many of those widely advertised uses.
Dr. Hsu put it bluntly in a separate report: “The evidence does not support the use of cannabis or cannabinoids at this point for most of the indications that folks are using it for.”
This is the point where the public should feel angry, not confused. Millions of people have been encouraged to believe cannabis is a broad medical solution. But the best science does not back that up for most conditions.
Where Cannabis Actually Performs Like Medicine
The review did find strong evidence in a few specific areas. The strongest support involves FDA approved cannabinoid medications used for particular conditions, including:
HIV or AIDS related appetite loss
Chemotherapy induced nausea and vomiting
Certain severe pediatric seizure disorders
These benefits are connected to specific, regulated medications with known formulations and controlled dosing. They are not the same as what most people buy in dispensaries.
The researchers emphasized that only “very few conditions” have cannabinoid therapies with clear, well established benefits supported by high quality clinical data.
Medical Cannabis vs Pharmaceutical Grade Products
One of the most important distinctions in the material is the difference between dispensary cannabis and pharmaceutical grade cannabinoids.
Medical cannabis sold in dispensaries can vary widely by potency, dose, and delivery method. People often inhale it daily, sometimes in high potency forms. That creates uncertainty and makes it harder to compare products to the doses used in controlled trials.
Pharmaceutical grade cannabinoid medicines are different. They are FDA approved, manufactured under strict standards, and prescribed through conventional pharmacies. The New York Times report highlighted medications like Marinol, Syndros, and Cesamet, which have shown good results for chemotherapy related nausea, appetite stimulation for debilitating illnesses like HIV or AIDS, and certain pediatric seizure disorders.
In other words, when cannabinoids behave like medicine, it is usually because they are treated like medicine.
Dispensary marketing often blurs this difference on purpose. That is one way the public gets conned. People hear “cannabinoid medication works for nausea in chemotherapy,” and it gets translated into “smoking weed helps with everything.”
A Hard Truth: Many “Medical” Users Are Really Recreational Users
The review and related reporting included a striking finding: nearly 30 percent of medical cannabis users met criteria for cannabis use disorder.
That is not a moral judgment. It is a medical red flag. It suggests that for a significant share of so called medical users, use is not controlled, not harmless, and not purely therapeutic.
Dr. Kevin Hill, a co author of the study, described the problem clearly. “There’s a whole other group of people who are saying they’re using it medically, but they’re really not,” he told The New York Times. “They’re just rationalizing their recreational use.”
This goes directly to the “conned by the industry” argument. The medical label gives people cover. It makes frequent intoxication sound like health care. It also creates a political shield for a commercial industry that wants as many daily users as possible.
How Many People Use Cannabis, and How Often
Alex Dimitriu, a psychiatrist and sleep medicine specialist who was not involved in the study, told Fox News Digital that cannabis is used by about 15 to 25 percent of U.S. adults in the past year.
Use is also becoming more frequent and more intense. A separate section of the source material reported that daily or near daily use has risen sharply over time. It cited that in 2000, 2.5 million Americans reported daily or near daily use, while by 2022 that number had grown to 17.7 million.
It also stated that more than 40 percent of people who use cannabis now take it daily or near daily, and these high frequency users consume most of the cannabis sold in the United States.
A market like that does not look like occasional, careful medical use. It looks like a consumption business.
Potency Has Exploded, and That Changes the Risk
The material also described how potency has risen dramatically. Until 2000, average potency of seized cannabis did not exceed 5 percent THC. Today, smokeable flower sold in licensed stores usually exceeds 20 percent THC. Concentrates such as vapes and dabs can be even more potent.
This matters because older long term studies often looked at a drug that barely exists anymore, lower potency cannabis used less frequently. Modern patterns, especially high potency daily use, create risks that older research is not fully designed to measure.
When people say, “Weed is safe,” they often mean the weed of decades ago, not the highly engineered products of the modern market.
The Dangers the Review Flagged
The JAMA review highlighted several safety concerns.
High potency cannabis use among young people was linked to higher rates of mental health issues, including psychotic symptoms and anxiety disorders. The material described this as a particular concern because young people are more vulnerable to mental health disruptions.
Daily inhaled cannabis use was also linked to increased risks of coronary heart disease, myocardial infarction, and stroke compared with non daily use.
This is a direct challenge to the casual cultural message that cannabis is harmless, especially when inhaled every day.
The authors urged clinicians to weigh potential benefits against known risks. They suggested screening patients for cardiovascular risk, evaluating mental health history, checking for drug interactions, and being careful about conditions where risks may outweigh benefits.
The main point was not complicated: do not assume cannabis is broadly effective, and do not pretend the risks are trivial.
How Big Is the Industry, and Why the Narrative Spread
The New York Times report described cannabis as a $32 billion industry. That kind of money shapes messaging. It also helps explain why the public perception raced far ahead of the evidence.
When an industry is that large, it does what industries do. It markets. It normalizes. It expands its customer base. It pushes the most flattering interpretation of the science.
The material also described how legalization has expanded consumption among adults, and how commercialization has helped spread high potency products and more accessible forms like edibles. It discussed misleading labels, regulatory loopholes, and the incentive for businesses to expand the market as prices fall and profit margins tighten.
In plain terms, the “medical marijuana” story became a sales strategy.President Donald Trump signaled this week he will loosen federal restrictions on cannabis. It also noted that he endorsed a Florida ballot initiative to legalize recreational use, even though Florida voters later voted it down.
There was also mention that the Trump administration may potentially reclassify marijuana, with Fox News senior medical analyst Dr. Marc Siegel discussing possible impacts of reclassification.
Those political developments make the timing of this review even more important. If federal policy is about to shift, the country should not be operating under illusions.
The Most Important Line in All of This
The strongest takeaway is simple. Dimitriu said it well: “This widely used substance is not a panacea.”
The review does not say cannabis has zero medical value. It says the best evidence supports only a short list of specific, FDA approved uses. It says many of the popular claims are not supported by strong science. It flags meaningful risks, including mental health concerns with high potency use in youth and increased cardiovascular risks tied to daily inhaled use. It also points out that nearly 30 percent of medical users meet criteria for cannabis use disorder.
That combination should change how the public talks about marijuana. It should also change how policymakers and doctors treat the term “medical marijuana.”
Dr. Hsu called for honesty: “Patients deserve honest conversations about what the science does and doesn’t tell us about medical cannabis,” he said.
After years of hype, that may be the closest thing to real medicine the cannabis debate has gotten.
HNZ Editor: The bottom line is that we have been conned into allowing yet another addictive recreational substance into our culture. It is dangerous, it causes mental damage, and we were lied to about “beneficial” effects.
